-transparent.png){kind=logo}
Deferoxamine (DFO), a widely used therapeutic iron chelator, was found to inhibit proliferation of the promyelocytic leukemia cell line HL-60 in a dose-dependent fashion when tested in a clonogenic assay at concentrations ranging from 1.0 to 10.0 microM. Cytosine arabinoside, methotrexate, and daunorubicin also produced dose-dependent inhibition of HL-60 colony growth when tested singly in vitro. When DFO, 1.0 microM, was included with each agent in dose-response studies, a synergistic enhancement of the antiproliferative effects was observed. This synergism probably results from a DFO-induced decrease in intracellular levels of deoxyribonucleoside triphosphates and an inhibition of the cells at the early S-phase of cell cycle. Our data suggest that DFO has potential as an adjunctive antileukemic agent.
Z Estrov, and
A Cohen, and
E W Gelfand, and
M H Freedman
January 1988,
Haematologica,
Z Estrov, and
A Cohen, and
E W Gelfand, and
M H Freedman
February 2003,
Acta pharmacologica Sinica,
Z Estrov, and
A Cohen, and
E W Gelfand, and
M H Freedman
January 1985,
Medical oncology and tumor pharmacotherapy,
Z Estrov, and
A Cohen, and
E W Gelfand, and
M H Freedman
May 2004,
Biochemical pharmacology,
Z Estrov, and
A Cohen, and
E W Gelfand, and
M H Freedman
January 1974,
Bulletin du cancer,
Z Estrov, and
A Cohen, and
E W Gelfand, and
M H Freedman
March 1993,
International journal of oncology,
Z Estrov, and
A Cohen, and
E W Gelfand, and
M H Freedman
January 1982,
Experimental pathology,
Z Estrov, and
A Cohen, and
E W Gelfand, and
M H Freedman
March 1999,
Annals of oncology : official journal of the European Society for Medical Oncology,
Z Estrov, and
A Cohen, and
E W Gelfand, and
M H Freedman
January 1990,
Haematology and blood transfusion,
Z Estrov, and
A Cohen, and
E W Gelfand, and
M H Freedman
March 1969,
Annals of internal medicine,
